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Abstract
BAK and BAX, which drive commitment to apoptosis, are activated principally by certain BH3-only proteins that bind
them and trigger major rearrangements. One crucial conformation change is exposure of their BH3 domain which
allows BAK or BAX to form homodimers, and potentially to autoactivate other BAK and BAX molecules to ensure
robust pore formation and cell death. Here, we test whether full-length BAK or mitochondrial BAX that are specifically
activated by antibodies can then activate other BAK or BAX molecules. We found that antibody-activated BAK
efficiently activated BAK as well as mitochondrial or cytosolic BAX, but antibody-activated BAX unexpectedly proved a
poor activator. Notably, autoactivation by BAK involved transient interactions, as BAK and BAX molecules it activated
could dissociate and homodimerize. The results suggest that BAK-driven autoactivation may play a substantial role in
apoptosis, including recruitment of BAX to the mitochondria. Hence, directly targeting BAK rather than BAX may prove
particularly effective in inhibiting unwanted apoptosis, or alternatively, inducing apoptosis in cancer cells.
Introduction
The BCL-2 family of proteins, which regulates the
mitochondrial (or intrinsic) pathway of apoptosis, com-
prises three subfamilies1–3. Signaling for apoptosis is
triggered by the BH3-only subset, such as BIM and BID,
but its essential mediators are the multidomain proteins
BAK and BAX, which, once activated, can generate pores
in the mitochondrial outer membrane (MOM) that
unleash proteolytic demolition of the cell by the caspases.
The prosurvival family members, such as BCL-2, BCL-XL,
and MCL-1 act by sequestering BH3-only proteins as well
as the activated BAK and BAX proteins. The canonical
interactions between family members involve a BH3
domain binding to a hydrophobic α2–α5 surface groove
on a globular family member4,5.
Prior to apoptotic signaling, BAK is inserted in the
MOM with its hydrophobic α9 helix forming a trans-
membrane domain6,7, whereas BAX is largely cytosolic
with its α9 partially sequestered in a hydrophobic α2–
α5 surface groove8–10. As depicted in Fig. 1, with the
initiation of apoptosis, BAK and BAX are activated by
BH3-only proteins. The remarkable ensuing conformation
changes include dissociation of the α1 helix, and separa-
tion of the α2–α5 core and α6–α8 latch domains which
also exposes their BH3 domain (in the α2 helix)11–15. The
unfolded activated BAK and BAX monomers can then
dimerize via reciprocal BH3:groove interactions to form
“symmetric homodimers”12,13,16–22 that cluster on the
MOM to release apoptogenic factors from the mito-
chondrial intermembrane space23–25. Alternatively, the
activated BAK and BAX monomers may bind to pro-
survival members to form heterodimers that do not par-
ticipate in pore formation26–30.
© Crown 2020
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Ruth M. Kluck (kluck@wehi.edu.au)
1Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville,
VIC 3052, Australia
2Department of Medical Biology, The University of Melbourne, Melbourne, VIC
3052, Australia
Edited by I. Amelio
Official journal of the Cell Death Differentiation Association
12
34
56
78
90
()
:,;
12
34
56
78
90
()
:,;
1
2
3
4
5
6
7
8
9
0
()
:,;
12
34
56
78
90
()
:,;
The activated BAK and BAX monomers are also pro-
posed to activate additional BAK and BAX molecules, a
process called auto-oligomerization or autoactivation
(Fig. 1)31–34. For example, once its BH3 domain is
exposed, a BAK or BAX monomer is postulated to act like
a BH3-only protein and trigger conformation change in
nonactivated BAK or BAX molecules. Autoactivation
would act as a feed-forward pathway to enhance the
likelihood that all pore-forming proteins in the cell
become engaged to ensure cell death. Autoactivation is
also proposed as a mechanism to promote BAX translo-
cation from the cytosol28,32.
Autoactivation appears plausible as the BAK and BAX
BH3 sequences closely resemble those of the activator
BH3-only proteins, including four hydrophobic (h1–4)
residues and an invariant aspartate residue
(Fig. S1a)12,14,35,36. Activation sites on the receptor BAK
and BAX molecules might include the canonical α2–
α5 surface groove12,14,37 or a modeled α1/α6 trigger
site32,38–40 (Fig. S1b). Several studies have shown that
BAK and BAX BH3 peptides can activate the full-length
proteins in mitochondrial and liposome assays12,13,36,41
and when injected into cells34. Even stronger activation by
the BAK and BAX BH3 domains was evident with chi-
meras of BID or BIM having their BH3 domain replaced
by that of BAK or BAX, probably because the chimeras
target to mitochondria29,36.
Determining whether full-length activated BAK and
BAX anchored at the MOM can activate other BAK or
BAX molecules has been more challenging. The concept
of BAK autoactivation (or auto-oligomerization) was
supported by the ability of an activated BAK mutant
(N-terminally truncated BAKΔN36) to trigger oligomer-
ization of endogenous BAK in mitochondria33. Evidence
of BAX autoactivation derived from experiments in which
liposomes that had been partially permeabilized by BAX
plus peptide and then fractionated away from excess
protein became further permeabilized by addition of full-
length BAX34. Other studies argue that BAX autoactiva-
tion occurs via the proposed α1/α6 trigger site, as a sta-
pled BAX BH3 peptide targeted that site32. The concept of
activation between full-length BAK and BAX proteins has
not been tested42, in part because activators that can
discriminate BAK and BAX have not been available.
We recently reported that antibodies can selectively
activate BAK or the mitochondria-targeted BAX variant
S184L43,44. For example, the 7D10 antibody binds to the
N-terminus of the BAK α1–α2 loop and triggers con-
formation changes and oligomerization of BAK. Anti-
bodies such as 3C10 that bind to the same region in BAX
activate the mitochondrial S184L variant via the same
mechanism. Unexpectedly, the BAX antibodies instead
inhibit wild-type (cytosolic) BAX by allosterically
sequestering its α9 transmembrane domain within its
surface groove, preventing BAX translocation to
mitochondria43,44.
Here, we have exploited antibody specificity for BAK or
BAX to test for autoactivation by the full-length BAK and
BAX proteins on mitochondria. Pairing different forms of
BAK and BAX revealed that antibody-activated BAK
could activate BAK, mitochondrial BAX and cytosolic
BAX, whereas activated BAX unexpectedly proved a poor
activator of all three targets. Curiously, the BAX groove
mutant, R109D, proved a robust activator. Despite the
potential of reciprocal BH3:groove interactions to simply
generate stable dimers, autoactivation by BAK involved a
transient interaction, as the targeted (activated) proteins
could homodimerize. The robust autoactivation we
observe with BAK indicates that developing direct acti-
vators of BAK (rather than of BAX) may best recruit
additional pore-forming BAK and BAX molecules to
induce robust apoptosis in cancer cells. Conversely, direct
inhibitors of BAK, by precluding autoactivation, may
prove particularly effective in inhibiting unwanted
apoptosis.
Materials and methods
Cloning and expression of BAK and BAX variants
For expression in cells, BAK and BAX mutants were
generated by site-directed mutagenesis and overlap
extension PCR, with BamHI and XhoI used for cloning
into the pMIH hygromycin selectable vector, and intro-
duced mutations confirmed by DNA sequencing, as
described17. The variants were then stably expressed in
Fig. 1 Schematic of BAK activation and autoactivation. In healthy
cells, nonactivated BAK is inserted into the mitochondrial outer
membrane via its α9 transmembrane domain. Activation can be
triggered by BH3-only proteins such as BID (by binding to the α2–α5
groove) or by antibody (binding to the N-terminus of the α1–α2 loop).
The major conformation changes that occur during activation include
separation of three components—the N-terminal α1–helix, the α2–α5
core, and the α6–α9 latch—leaving the protein with an exposed BH3
domain (α2; red triangle) and a modified α2–α5 hydrophobic groove.
(BAK conformation change is also illustrated in an animation of
autoactivation in Fig. S6.) Once activated, the BAK monomer can bind
to other family members to form either homodimers that promote
apoptosis, or heterodimers with a pro-survival relative (here MCL-1)
that do not contribute to pore formation. The activated monomer
may also activate (autoactivate) additional BAK (or BAX) molecules.
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SV40-immortalized Bak−/−Bax−/− mouse embryonic
fibroblasts (MEF), and polyclonal populations of green
fluorescent protein-positive cells or hygromycin-resistant
MEF selected and cultured as described17.
Recombinant BAXR109D and BAXR34A were generated
by site-directed mutagenesis of human wild-type or cys-
null BAX, respectively38,44, and the recombinant wild-type
and mutant BAX proteins expressed and purified as
described9.
Preparation of mitochondrial fractions from MEF and
mouse liver
Mitochondria-enriched membrane fractions from MEF
were generated by first resuspending cells at 1 × 107 ml−1
in MELB buffer (93.5 mM sucrose, 20 mM HEPES, pH
7.4, 2.5 mM MgCl2 and 100 mM KCl) supplemented with
Complete Protease Inhibitor cocktail (Roche). Cell
membranes were then permeabilized by addition of
0.025% w/v digitonin and incubation on ice for 10min,
followed by centrifugation at 13,000g for 5 min to separate
the supernatant (cytosolic) and pellet (mitochondria-
enriched membrane) fractions. Membrane fractions were
resuspended in MELB buffer supplemented with Com-
plete Protease Inhibitor cocktail as above. Mouse liver
mitochondria (MLM) were prepared from wild-type or
Bak−/− C57BL/6 wild-type mice as described36.
Assessment of BAX membrane insertion, BAK and BAX
conformation change and oligomerization
Membrane insertion of BAX (expressed in cells or
recombinant protein added to MLM) was assessed by
sodium carbonate extraction, as described38. BAK and
BAX conformation change was assessed by limited pro-
teolysis, as described45. Cyseine linkage was used to
assess oligomerization of BAK and of BAX-S184L, as
described45.
Mitochondrial incubations and cytochrome c release
assays
For activation of BAK or BAX-S184L in permeabilized
MEF, membrane fractions (50 μl) were incubated with
100 nM caspase-8-cleaved human Bid (cBID)46 or with
the indicated antibody (0.1 mg/ml) for 30min at 30 °C.
The 7D10 and 3C10 antibodies are rat monoclonal anti-
bodies generated in house, as previously described43. The
7D10 single chain variable fragment (scFv) was kindly
generated by Commonwealth Serum Laboratories, Mel-
bourne. For incubations based on mitochondria from
mouse liver, MLM were diluted to 1mg/ml in MELB and
supplemented with the indicated concentrations of
recombinant human BAX variants and cBID, and samples
incubated for 1 h at 37 °C. Stock solutions of recombinant
BCL-2 proteins were diluted in MELB+ 1% bovine serum
albumin to prevent adsorption to plasticware as
described47. To monitor cytochrome c release from
mitochondria, reactions were spun at 13,000g (10,000g for
MLMs) and the supernatant and pellet fractions immu-
noblotted for cytochrome c.
Co-immunoprecipitation
Membrane fractions (at least 2.5 × 106 cells per treat-
ment) were solubilized with 1% w/v digitonin in lysis
buffer (20 mM Tris, 135mM NaCl, 1.5 mM MgCl2, 1 mM
EGTA, 10% glycerol, pH 7.4) for 1 h on ice. Lysates were
centrifuged at 13,000g for 5 min and supernatants col-
lected. (No pre-clearing step with Protein G sepharose
was performed because the 7D10 and 3C10 antibodies
had been added for activation.) Solubilized samples were
added to Protein G sepharose, and, where indicated, also
supplemented with 4 μg conformation-specific BAK
(14–36) or BAX (6A7) antibody and incubated for 1–2 h
at 4 °C. Unbound proteins were collected and the resin
washed with lysis buffer containing up to 0.1% w/v digi-
tonin. Immunoprecipitated proteins (IP) were eluted by
boiling in sample buffer, and together with unbound and
total lysates (input), were immunoblotted for BAK and
BAX as indicated. To minimize signals from antibody
light chains in western blots, heavy chain-specific horse-
radish peroxidase (HRP)-conjugated goat anti-rabbit and
anti-mouse IgG was used as secondary antibody.
SDS-PAGE and western blotting
Samples were resolved by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) (Bio-Rad
or Invitrogen NuPAGE Bis–Tris for limited proteolysis)
and transferred to 0.22 μm nitrocellulose or poly-
vinylidene fluoride membranes. Primary antibodies
included rabbit polyclonal anti-BAK aa23–38 (1:5000,
Sigma #B5897, RRID:AB_258581), anti-BAK NT (1:2,000,
Millipore #06-536, RRID:AB_310159), anti-BAX NT
(1:1000, Millipore #ABC11, RRID:AB_310143), rat
monoclonal anti-BAK (clone 4B5, in-house), anti-BAX
(clone 49F9, in-house), mouse monoclonal anti-BAX
clone 3 (1:2000, BD Pharmingen #BDB610982, RRID:
AB_398295), anti-cytochrome c (1:2000, BD Pharmingen
#556433, RRID: AB_396417) and anti-FLAG M2 (1:2,000,
Millipore #F1804, RRID: AB_262044)). Detection was
achieved using HRP-conjugated anti-rabbit (1:5000,
Southern Biotech #4010-05, RRID: AB_2632593), anti-rat
(1:5000, Southern Biotech #3010-05, RRID: AB_2795801)
and anti-mouse (1:2000, Southern Biotech #1010-05,
RRID: AB_2728714) secondary antibodies. To avoid sig-
nals from antibody light chains in western blots, heavy
chain-specific HRP-conjugated goat anti-rabbit IgG
(1:5000, Southern Biotech #4041-05, RRID: AB_2795946),
and goat anti-rat IgG (1:5000, Southern Biotech #3030-05,
AB_2716837) were also used. Proteins were visualized by
Luminata Forte Western HRP substrate (Millipore
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#WBLUF0500) on a ChemiDoc XRS+ System, and ima-
ges processed with ImageLab Software (Bio-Rad).
Results
To test for autoactivation between full-length BAK and
BAX proteins, pairs of the BAK and BAX variants were
co-expressed or combined (Table S1) and stimulated with
an antibody that directly activates only one of the two
proteins. We note that “activation” is used here to denote
the early structural unfolding of BAK and BAX to expose
the BH3 domain, rather than the final functional step of
pore formation (see Fig. 1). “Autoactivation” occurs
between BAK and BAK, BAX and BAX, or BAK and BAX
molecules, and is distinct from “spontaneous activation”.
Antibody-activated BAK activates BAKG51C
To test for autoactivation of BAK by BAK, as depicted
in Fig. 2a, we exploited the ability of the 7D10 antibody to
activate wild-type human BAK but not the G51C variant,
in which the 7D10 epitope is mutated43. The two proteins
were stably expressed either individually or together in
Bax−/−Bak−/− MEF. The BAKG51C variant was dis-
tinguished by an N-terminal FLAG-tag (i.e., F-BAKG51C).
The cells were permeabilized and the membrane fractions
incubated with cBID (caspase-8 cleaved BID) to activate
both wild-type BAK and F-BAKG51C, or with the 7D10
antibody to directly activate only wild-type BAK. Activa-
tion of the co-expressed F-BAKG51C was then assessed by
three methods.
We first assessed the ability of F-BAKG51C to form
dimers with 7D10-activated BAK, as detected by immu-
noprecipitation with 7D10. As expected, when the BAK
variants were expressed individually and stimulated with
7D10 antibody, 7D10 precipitated most of the wild-type
BAK (Fig. 2b, lower panels, lane 3), but not F-BAKG51C
(lane 6). Importantly, with co-expressed WT BAK and F-
BAKG51C, 7D10 also captured F-BAKG51C (Fig. 2b, upper
and lower panels, lane 9), indicating complexes of acti-
vated wild-type BAK and F-BAKG51C (Fig. 2c).
A second set of experiments involved immunoprecipi-
tation with a rabbit antibody (14–36) that recognizes the
activated forms of both wild-type BAK and F-BAKG51C; it
was added to all samples at the end of the incubations
(Fig. S2a). Again, F-BAKG51C was immunoprecipitated
from 7D10-treated samples only if wild-type BAK was
also present (Fig. S2b, lane 9 vs. 6). Notably, as nearly all
the F-BAKG51C was immunoprecipitated by the 14–36
antibody, its activation was nearly complete. Thus, the
autoactivation by antibody-activated BAK was robust.
Finally, we assessed F-BAKG51C activation using dis-
ulfide linkage to detect oligomerized proteins (Fig. S2b).
When 7D10 was incubated with co-expressed wild-type
BAK (C14 and C166) and F-BAKG51C, linkage generated
three distinct 2× complexes (Fig. S2b, lane 6). Based on
size, the two upper complexes contain the larger FLAG-
tagged F-BAKG51C, indicating that it had become auto-
activated by wild-type BAK and could be linked to either
activated BAK or activated F-BAKG51C. Autoactivation
was again near-complete, as most F-BAKG51C could be
linked into 2× complexes (Fig. S2b, lane 6). In summary,
three methods of detecting activated F-BAKG51C (co-
immunoprecipitation, immunoprecipitation, and cysteine
linkage) showed that 7D10-activated BAK efficiently
autoactivated BAKG51C.
Antibody-activated BAK can activate mitochondrial BAX
To test whether BAK can activate BAX when both are
located on the MOM, we co-expressed BAK and
mitochondria-targeted BAX-S184L (with cysteine sub-
stitutions in the BH3 domain (S55C) and groove (R94C)),
and incubated the membrane fractions with 7D10 anti-
body to directly activate BAK (Fig. 3a).
We first assessed activation of BAK and BAX-S184L
using limited proteolysis by proteinase K. As illustrated in
Fig. 3b, it cleaves nonactivated BAK and BAX at their far
N- and C-termini, respectively, but their activation
exposes cleavage sites in the α1–α2 loop, and the cleaved
fragments can be identified by the relevant antibodies,
4B5 for BAK and clone 3 for BAX45. As expected, cBID
added to the membrane fractions activated both BAK and
BAX-S184L, whether expressed individually or together
(Fig. 3c, lanes 3, 7, and 11). In addition, the 7D10 antibody
activated BAK but not BAX-S184L when individually
expressed (Fig. 3c, lanes 4 and 12). However, when BAK
and BAX-S184L were co-expressed, 7D10 also activated
BAX-S184L to an extent similar to cBID (Fig. 3c, lower
panel, lane 8 vs. 7). Thus, 7D10-activated BAK efficiently
activated full-length BAX anchored in the mitochondrial
outer membrane.
We next demonstrated activation of BAX-S184L by
its ability to form oligomers, as assessed by co-
immunoprecipitation (Fig. 3d) or linkage (Fig. S3). BAX-
S184L immunoprecipitated with the 7D10 antibody if and
only if BAK was present (Fig. 3d, upper panels, lane 9 vs. 3
and 6), indicating that a portion of BAX-S184L had
become activated and could dimerize with activated BAK
(Fig. 3e). In addition, a large portion of BAX-S184L
formed homodimers following 7D10 treatment, as shown
by disulfide linkage between cysteines in its BH3 domain
and groove (S55C:R94C reciprocal linkage), but again
only when BAK was present (Figure S3, upper panel, lane
12 vs. 8).
In summary, three methods of detecting activated BAX-
S184L (limited proteolysis, co-immunoprecipitation,
cysteine linkage) showed that 7D10-activated BAK could
activate this mitochondrial form of BAX, and that its
activation was near-complete. Furthermore, because BH3:
groove dimers formed between the activated BAX-S184L
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molecules (Fig. S3), autoactivation can be a transient or
“hit-and-run” process, similar to activation by BH3-only
proteins such as BID and BIM, which dissociate from the
activated monomer.
Antibody-activated BAK at mitochondria recruits and
activates wild-type BAX
To determine if BAK could also activate cytosolic wild-
type BAX, we combined BAX with mitochondria that
contained BAK and incubated the mixture with 7D10
(Fig. 4a). In one approach, recombinant BAX was incu-
bated with permeabilized MEF, either Bak−/−Bax−/−
MEF or those cells expressing human BAK (Fig. 4b). The
samples were then centrifuged, and the pelleted mem-
brane fractions subjected to carbonate extraction to
separate peripherally attached from membrane-inserted
proteins. As expected, cBID elicited BAX translocation
and insertion into the mitochondria-enriched membrane
fraction, in the presence or absence of BAK (Fig. 4b, lanes
8 and 17). BAX translocation and MOM insertion also
followed 7D10 treatment, but only if BAK was present
(Fig. 4b, lane 18 vs. lane 9). Thus, antibody-activated BAK
can recruit BAX to insert into the MOM, and at an effi-
ciency comparable to cBID.
A second approach used HeLa cells to test activation
between endogenous BAK and BAX proteins. Permeabi-
lized HeLa cells were incubated with cBID, 7D10, or
3C10, and the cytosol and membrane fractions separated
and assessed for BAK and BAX activation (Fig. 4c). As
expected, either cBID or 7D10 activated BAK, as indicated
by limited proteolysis (Fig. 4c, upper panel, lanes 8 and 9).
Notably, either cBID or 7D10 also promoted BAX acti-
vation, as shown by the proteinase K-cleaved BAX in the
membrane fraction (Fig. 4c, lower panel, lanes 8 and 9).
As a negative control, the anti-BAX antibody 3C10 did
not trigger BAX translocation or activation (Fig. 4c, lower
panel, lane 10), and decreased proteinase K cleavage of
BAX α9 (Fig. 4c, lower panel, lane 5), as we reported
previously43,44. In summary, 7D10-activated BAK can
activate the BAX present in HeLa cytosol, and to an
extent equivalent to cBID.
Antibody-activated mitochondrial BAX-S184L does not
activate BAK
As antibody-activated BAK could activate both BAK
and BAX in a variety of contexts, we next tested if
antibody-activated BAX also had this ability. This seemed
likely as BAX BH3 peptides and BIDBAXBH3 chimeras
strongly activated both BAK and BAX in mitochondrial
experiments29,36.
We first explored if mitochondria-targeted BAX-S184L
activated by the 3C10 antibody could activate BAK (Fig. 5a).
Limited proteolysis indicated that 3C10 could activate
BAX-S184L as expected (Fig. 5b, upper panel, lanes 8 and
Fig. 2 Antibody-activated BAK activates BAKG51C. a Schematic of
two BAK variants (BAK and F-BAKG51C) co-expressed in mitochondria and
then incubated with the 7D10 antibody to directly activate BAK and
expose its BH3 domain (red triangle). 7D10 cannot bind F-BAKG51C. b Co-
immunoprecipitation shows that F-BAKG51C is activated by the 7D10
antibody if BAK is also present. Two BAK variants were expressed
individually or together in Bax−/−Bak−/− mouse embryonic fibroblasts
(MEF), and membrane fractions incubated with the 7D10 antibody to
activate (wild-type) BAK. As positive controls, aliquots were also
incubated with cBID to activate both forms of BAK. Samples were
immunoprecipitated using the 7D10 antibody, and immunoblotted for
FLAG (upper panels) or BAK (lower panels). Data are representative of
two independent experiments. c Schematic of BAK dimers captured by
the 7D10 antibody. Activated BAK and activated F-BAKG51C associate to
form homodimers, some of which 7D10 can immunoprecipitate.
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12), but BAK remained in its nonactivated form (Fig. 5b,
lower panel, lanes 4 and 8). When assessed by oxidant-
induced cysteine linkage, 3C10 produced BAX-S184L
homodimers as expected (Fig. 5c, upper panel, lanes 6
and 9). However, no activation of BAK was evident, as
indicated by the absence of 2× complexes and the presence
of the nonactivated BAK Mx band (intramolecular cysteine
linkage that is a hallmark of nonactivated BAK) (Fig. 5c,
lower panel, lane 6). Thus, full-length mitochondrial BAX-
S184L is a poor activator of BAK.
Fig. 3 Antibody-activated BAK can activate mitochondrial BAX. a Schematic of BAK co-expressed with a mitochondrial form of BAX (BAX-S184L)
and incubated with the 7D10 antibody to activate BAK. b Major proteinase K cleavage sites in activated BAK and BAX locate to the α1–α2 loop
region. Fragment sizes detected by the 4B5 or clone 3 antibody (see Fig. 3c) are shown. Note that activated BAK is cleaved to a 17 kDa fragment
(rather than a 15 kDa fragment) when 7D10 antibody is bound, because the antibody masks a cleavage site. c Conformation change in BAX-S184L is
triggered by 7D10 antibody if BAK is also present. BAK and BAX-S184L were expressed individually or together in Bax−/−Bak−/− MEF, and membrane
fractions incubated with the 7D10 antibody to activate BAK. As positive controls, aliquots were also incubated with cBID to activate both BAK and
BAX-S184L. Samples were then incubated with proteinase K and western blotted to reveal fragments corresponding to nonactivated and activated
forms of BAK (upper panel) or BAX-S184L (lower panel). Data are representative of two independent experiments. d Co-immunoprecipitation shows
that BAX-S184L is activated by 7D10 antibody if BAK is also present. Membrane fractions were treated as in (c) and immunoprecipitated with 7D10,
which had been added to the incubations to activate BAK. The samples were then immunoblotted for BAX-S184L (upper panels) or BAK (lower
panels). Data are representative of two independent experiments. e Schematic of BAK and BAX-S184L dimers captured by the 7D10 antibody in panel
(d). Activated BAK and activated BAX-S184L associate to form dimers, some of which 7D10 can immunoprecipitate.
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Mitochondrial BAX-S184L is a poor activator of
mitochondrial BAX-S184LR34A
To test for activation between BAX molecules residing
in the MOM, we exploited the R34A mutation, which
abrogates binding of 3C10 to BAX44. We paired F-BAX-
S184L with BAX-S184LR34A and directly activated the
former with the 3C10 antibody (Fig. 5d). One set of
samples was then immunoprecipitated for the 3C10
antibody that had been added as the stimulus, while
another set of samples was supplemented with the 6A7
antibody to immunoprecipitate all forms of activated
BAX-S184L. As expected, the addition of 6A7 allowed
immunoprecipitation of both BAX-S184L variants from
the cBID incubations (Fig. 5e, upper panels, lanes 2, 5, 8
vs. 1, 4, and 7). However, 6A7 did not allow immuno-
precipitation of the R34A variant from 3C10-treated
samples (Fig. 5e, upper panels, lanes 6 and 9). Thus, even
if F-BAX-S184L was present and able to be activated by
3C10, it was a poor activator of BAX-S184LR34A.
Mitochondrial BAX-S184L is a poor activator of cytosolic
BAXR34A
To test for activation of cytosolic BAX by mitochondrial
BAX-S184L, we paired F-BAX-S184L with recombinant
BAXR34A and again directly activated the former with the
3C10 antibody (Fig. 5f). To provide relevant controls,
incubations included membrane fractions from three
types of cells: Bak−/−Bax−/− MEF and those cells re-
expressing either F-BAX-S184L or BAK. Recombinant
BAXR34A was added to all incubations and direct activa-
tion of F-BAX-S184L or BAK initiated with cBID, 3C10,
or 7D10 (Fig. 5g). Samples underwent carbonate extrac-
tion to identify BAX that had inserted into the MOM. As
expected, cBID triggered BAXR34A to translocate and
insert into mitochondria (Fig. 5g, lower panel, lanes 2, 5,
and 8 vs. 1, 4, and 7). In addition, the 7D10 antibody
triggered insertion of BAXR34A in the presence of BAK
(Fig. 5e, lower panel, lane 9 vs. 7), confirming the ability of
BAK to activate cytosolic BAX (Fig. 4b). Notably, while the
3C10 antibody increased insertion of F-BAX-S184L, some
of which may be peripherally attached, increased insertion
of BAXR34A was not evident (Fig. 5g, lower panel, lane 6 vs.
4). Thus, even if F-BAX-S184L was activated by 3C10, it
was a poor activator of cytosolic BAX.
Mutation in its hydrophobic groove converts BAX into a
strong activator
We next considered whether poor autoactivation by
full-length activated mitochondrial BAX might be due to
incomplete exposure of the BH3 domain, or to an inability
to access the activation sites in nonactivated BAK or BAX.
To explore this, we exploited the ability of intermediate
levels of BAX to permeabilize mitochondria even in the
Fig. 4 Antibody-activated BAK at mitochondria recruits and
activates wild-type BAX. a Schematic of BAK combined with wild-
type BAX and incubated with the 7D10 antibody to activate BAK.
b Translocation and MOM insertion of recombinant BAX is triggered
by 7D10 if BAK is also present. Bax−/−Bak−/− MEF or those cells
expressing BAK were permeabilized and supplemented with 20 nM
recombinant BAX, then incubated with 7D10 to activate BAK. As
positive controls, aliquots were also incubated with cBID to activate
both BAK and BAX. Samples were then centrifuged to recover the
supernatant (Sup). The pellet fraction was then subjected to
carbonate extraction to separate peripherally attached (Periph) and
membrane-inserted (Insert) BAX. The three fractions were then
immunoblotted for BAX. Data are representative of three
independent experiments. c Translocation and activation of
cytosolic BAX in permeabilized HeLa cells incubated with 7D10.
HeLa cells were permeabilized and incubated with cBID, the 7D10
antibody to BAK, or the 3C10 antibody to BAX. The cytosolic and
membrane fractions were then incubated with proteinase K and
blotted for BAK (upper panel) or BAX (lower panel). Data are
representative of two independent experiments. *Inhibitory effect of
3C10 on cytosolic BAX44 is evident from the inability of proteinase K
to cleave α9. # Cross-reactive fragments from 7D10 and 3C10
antibodies.
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absence of an apoptotic stimulus such as cBID. Others
have shown that in cells deficient for all BCL-2 family
proteins, BAX expression alone was sufficient to induce
apoptosis48. To enhance the likelihood of BAX BH3
exposure, we also tested the groove mutant BAXR109D
(Fig. 6a), which has a low affinity for cBID12,38. We rea-
soned the low affinity for BH3 domains may also reduce
BH3:groove homodimer formation.
Before testing for BAX autoactivation of BAK, we
assessed the intrinsic pore-forming activity of the two
BAX variants in Bak−/− MLM (Fig. 6b). As previously
observed38, in response to cBID, low levels of BAX but not
BAXR109D released cytochrome c from Bak−/− MLM
(Fig. 6b, lane 3 vs. 10). In the absence of cBID, however,
200 nM of either BAX variant released cytochrome c
(Fig. 6b, lanes 5 and 12). Moreover, pore formation by this
concentration of BAX was BH3-dependent, as an anti-
body (10F4) to the BAX BH3 region (e.g., α2–α3 hinge,
residues 66–78) blocked cytochrome c release (Fig.
S4a–d). We previously reported similar inhibition of
BAK-induced cytochrome c release by an antibody (4B5)
to the BAK α2–α3 hinge region17. Notably, 10F4 did not
inhibit BAX or BAXR109D translocation (Fig. S4e), indi-
cating that translocation is not due to BAX BH3 exposure
in a portion of the recombinant BAX proteins. These
experiments in Bak−/− MLM establish that intermediate
levels of either BAX or BAXR109D induce cytochrome c
release in a BH3-dependent manner.
Since both BAX variants exposed their BH3 domain
under these conditions, we next tested their ability to
activate BAK by incubating each with MLM, which con-
tains mouse BAK (mBAK; Fig. 6a). Strikingly, mBAK was
activated by 100 nM (or higher) BAXR109D (Fig. 6c, lower
panel, lanes 11–15) and contributed to cytochrome c
release (compare lane 11 in Fig. 6b and c, upper panel). In
contrast, mBAK was not activated by even 500 nM of
wild-type BAX alone (Fig. 6c, lower panel, lanes 4–8).
Autoactivation by BAXR109D required its BH3 domain, as
the 10F4 antibody prevented mBAK activation (Fig. S4d,
lower panels, lanes 20–22 vs. 9–11). Thus, the groove
mutation allowed full-length activated BAX to activate
BAK, which promoted release of cytochrome c.
In summary, in the absence of cBID, intermediate
concentrations of full-length BAX or BAXR109D could
translocate to the mitochondrial fraction and expose the
α2–α3 region as a step toward cytochrome c release.
Exposure of the α2–α3 region in BAXR109D (but not wild-
type BAX) provoked BAK activation, indicating that the
BH3 domain in the activated BAXR109D monomer can
access the activation site in mBAK.
Discussion
The concept of autoactivation arose from the ability of
truncated versions of BAK and BAX to activate full-length
BAK and BAX33. To investigate whether autoactivation can
occur between full-length proteins located on the MOM,
we co-expressed or co-incubated pairs of BAK and BAX
variants and specifically activated one of the variants with
an antibody, then tested whether that variant could activate
the paired protein. We found that full-length BAK was a
strong activator of each partner (Figs. 1–4). Surprisingly,
despite the very similar structure and function of BAK and
BAX in most analyses, both full-length BAX and BAXS184L
proved weak activators of their partners (Figs. 5 and 6).
(see figure on previous page)
Fig. 5 Antibody-activated mitochondrial BAX-S184L is a poor activator of BAK, BAX-S184L, and BAX. a Schematic of BAX-S184L co-expressed
with BAK and incubated with 3C10 antibody, which directly activates BAX-S184L. b Conformation change in BAK is not triggered by 3C10 antibody,
even if BAX-S184L is activated. BAX-S184L and BAK were expressed individually or together in Bax−/−Bak−/− MEF, and membrane fractions incubated
with the 3C10 antibody to activate BAX-S184L. As positive controls, aliquots were also incubated with cBID to activate both BAX-S184L and BAK.
Samples were then incubated with proteinase K and western blotted to reveal fragments corresponding to nonactivated and activated forms of BAX-
S184L (upper panel) or BAK (lower panel). Data are representative of two independent experiments. c Oligomerization of BAK is not triggered by
3C10 antibody, even if BAX-S184L has been activated and oligomerized. Aliquots from (b) were incubated with oxidant (CuPhe) to detect
oligomerization. Note that BAX-S184L linkage at S55C:R94C detects BH3:groove homodimers (see schematic in Fig. S3), and that BAK linkage detects
both C14:C166 linkage within nonactivated BAK (Mx) and linkage within and between dimers (2X). Data are representative of two independent
experiments. d Schematic of F-BAX-S184L co-expressed with the BAX-S184LR34A variant and then incubated with 3C10 which directly activates BAX-
S184L but not the R34A variant. e Immunoprecipitation shows that BAX-S184L is a poor activator of BAX-S184LR34A. BAX-S184L and BAX-S184LR34A
were expressed individually or together in Bax−/−Bak−/− MEF, and membrane fractions incubated with the 3C10 antibody to activate BAX-S184L. As
positive controls, aliquots were also incubated with cBID to activate both BAX-S184L variants. The pellet fractions were then solubilized and an
aliquot taken for the input sample. Additional aliquots were immunoprecipitated either with (upper panels) or without (lower panels) addition of the
6A7 antibody that binds to activated BAX, and the samples immunoblotted for BAX. Note that the beads used in the immunoprecipitation would
bind both the 3C10 and 6A7 antibodies. Data are representative of two independent experiments. f Schematic of BAX-S184L combined with
recombinant BAXR34A and incubated with the 3C10 antibody to directly activate BAX-S184L. 3C10 cannot bind the BAXR34A variant. g BAX-S184L is a
poor activator of recombinant BAXR34A. Membrane fractions from Bax−/−Bak−/− MEF or those cells expressing BAX-S184L or BAK were supplemented
with 50 nM recombinant BAXR34A and incubated with cBID or the 3C10 or 7D10 antibody. Samples were then subjected to carbonate extraction as in
Fig. 4b and the supernatant (Sup.) and inserted (Insert.) fractions blotted for BAX. Note that F-BAX-S184L is partly peripherally attached, but becomes
activated and inserted following either cBID or 3C10 treatment (lanes 5 and 6). Data are representative of three independent experiments.
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The robust ability of BAK but not BAX to activate other
effector molecules suggests a significant difference
between their exposed BH3 domains in the context of the
full-length proteins. As peptides, and even in the context
of chimeric BID proteins, the BAX BH3 sequence seems
as potent as the BAK BH3 in activating BAK or BAX29,36,
with some exceptions13. The inactivity of BAX is not
explained by the exposed BH3 domain adopting the
incorrect orientation for binding to other BAK or BAX
molecules, as BAXR109D could autoactivate mouse BAK in
a BH3-dependent manner (Figs. 6 and S4). One possibility
is that the half-life of the activated BAX monomer is very
short compared to that of the activated BAXR109D
monomer, due to the R109D groove mutation slowing
conversion to symmetric homodimers. Activated BAK
may also be slow to dimerize, at least compared to wild-
type BAX. The basis for slow dimerization of BAK but not
BAX is unclear because the BAK and BAX α2–α5 core
domain homodimers show similar shape complementarity
and buried surface area (personal communication, Peter
Colman). However, other factors such as initial binding
affinities or lateral mobility in the MOMmay differ for the
activated BAK and BAX monomers.
While our experiments are largely based on using
antibodies rather than physiological stimuli (e.g., BH3-
only proteins) to trigger initial activation of BAK or BAX,
our findings may also hold for BH3-only signaling. One
consideration was that the extra bulk of the 7D10 anti-
body bound to the flexible N-terminus may slow BAK
homodimerization and increase the window in which the
monomer can act as an activator. However, an attached
antibody might be expected to affect BAK and BAX
similarly, as the structures of BAK homodimers and BAX
homodimers are similar12,13. In addition, BAK activated
by the small 7D10 single-chain variable fragment
(~25 kD) rather than the full IgG antibody (~150 kD) was
also a strong autoactivator (Fig. S5). Finally, even without
antibody-activation, wild-type BAX was a poor activator
(Figs. 6 and S4).
The activation site(s) on BAK, BAX-S184L, and wild-
type BAX (Fig. S1b) must be accessible to the exposed
BH3 domain of BAK. For BAK activation of cytosolic
Fig. 6 Mutation in hydrophobic groove converts BAX into a strong activator. a Schematic of recombinant BAXR109D incubated with BAK-
expressing mouse liver mitochondria. b In the absence of an activating stimulus (e.g., no cBID or activating antibody), intermediate levels of BAX or
BAXR109D can permeabilize Bak−/− mitochondria. Mouse liver mitochondria (MLM) from Bak−/− mice were incubated with increasing levels of
recombinant BAX or the groove mutant BAXR109D and assessed for cytochrome c release. As positive controls, additional aliquots were incubated
with 10 nM cBID and 10 nM BAX proteins. Data are representative of four independent experiments. c Activated BAXR109D but not wild-type BAX is
able to autoactivate BAK. MLM from wild-type mice were incubated as in (b) and assessed for cytochrome c release (upper panels) and activation of
mouse BAK (by proteinase K cleavage, lower panels). Data are representative of four independent experiments.
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BAX, BAX must locate to the MOM. This BAX might
correspond to the population that is peripherally attached
to the MOM49, or that associates with VDAC250, or that
retrotranslocates to the cytosol51–53. Cytosolic BAX may
also collide with mitochondria without requiring a
translocation stimulus29. Interestingly, BAK activation of
BAX may contribute significantly to BAX translocation
and activation (Figs. 4 and 5g), consistent with recent
genetic evidence that either BAK or VDAC2 can promote
BAX translocation and activation54. However, contrary to
previous studies32,34, our data provide little evidence that
BAX directly contributes to BAX translocation or
activation.
Our data also address whether autoactivation involves a
transient interaction (hit-and-run) or a stable reciprocal
BH3:groove interaction (hit-and-stay) (Fig. 7a). For
example, because both activated BAK and its targeted
BAK or BAX molecules possess a hydrophobic groove, an
Fig. 7 Summary. a Schematic of the transient interaction involved in autoactivation by BAK. The α2–α5 hydrophobic groove activation site in BAK is
used to illustrate the hit-and-run interaction involved in its activation by BH3-only proteins (left panel). Autoactivation also involves a transient
interaction (middle panel) as the targeted BAKG51C and BAX-S184L proteins became nearly fully activated and could homodimerize rather than
remain bound to BAK (see Figs. S2, 3c, and S3). Whether a proportion of targeted molecules can remain bound to BAK as a BH3:groove dimer (right
panel; hit-and-stay) has not been determined. b The transient interaction involved in autoactivation by BAK (left panels) highlights the potential of
directly targeting BAK to either inhibit or promote apoptosis, whereas direct BAX activation (right panels) is expected to be less productive.
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initial unidirectional BH3:groove interaction may progress
to reciprocal BH3:groove interactions, to generate a dimer
that cannot itself be an activator. Our data indicate,
however, that the activating interaction is often transient,
as 7D10-activated BAK activated most of the co-
expressed BAKG51C (Fig. S2a, b) and BAX-S184L
(Fig. S3b) proteins. Furthermore, a large proportion of
the autoactivated proteins did not remain bound to BAK.
For example, only a proportion of BAKG51C molecules co-
precipitated with 7D10-activated BAK (Fig. 2b, lane 9)
despite all BAKG51C being activated (Fig. S2a, b). Fur-
thermore, most BAX-S184L formed homodimers that
could be linked via a BH3:groove interaction within those
dimers (Fig. S3). The transient interaction involved in
autoactivation may be explained just as for activation by
BH3-only proteins12,14,37,55,56: binding induces major
conformation change in the α2–α5 activation site (or α1/6
pocket) to decrease affinity for the activator (see anima-
tion in Fig. S6).
The transient nature of BAK autoactivation implies a
catalytic process that may be important to recruit suffi-
cient BAK and BAX into homodimers to ensure apoptotic
death (Fig. 7b). If signaling by BH3-only proteins is lim-
iting, any BAK that became activated could augment that
signal to activate more BAK (and BAX) to push the cell
over the threshold of BAK and BAX homodimerization
required for pore formation. Notably, BAK is not
expressed in differentiated neurons57–59. Its silence there
may have evolved to protect the neuronal system against
accidental apoptosis, by removing both BAK’s intrinsic
pore-forming capacity and the feed-forward nature of
autoactivation.
The prosurvival BCL-2 proteins, especially MCL-1 and
BCL-XL, can sequester activated BAK, an inhibition
process referred to as Mode 227–29,60–62 (see Fig. 1).
Sequestration involves binding of the exposed BAK BH3
domain, which would inhibit not only homodimer for-
mation, but autoactivation, as argued previously31,34,48,63.
Thus, in cancer cells that resist treatment due to increased
prosurvival proteins, the proteins may act in part via
preventing autoactivation by BAK. Accordingly, inhibitors
of prosurvival proteins, in particular BH3 mimetics that
target MCL-1 and BCL-XL that are currently in clinical
trials64, may act in part by promoting autoactivation
by BAK.
Several means of directly regulating BAK and BAX have
been reported, as reviewed in ref. 2. Autoactivation by BAK
implies that activators or inhibitors of BAK rather than of
BAX, may be important therapeutic agents. Direct acti-
vators of BAK may best recruit additional pore-forming
BAK and BAX molecules to induce robust apoptosis in
cancer cells. Direct inhibitors of BAK, including small
molecules65, by precluding autoactivation, may be parti-
cularly effective in inhibiting unwanted apoptosis.
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